Zobrazeno 1 - 2
of 2
pro vyhledávání: '"X. E. Luepke-Estefan"'
Autor:
P. Guisado-Vasco, M. M. Carralón-González, J. Aguareles-Gorines, E. M. Martí-Ballesteros, M. D. Sánchez-Manzano, D. Carnevali-Ruiz, M. García-Coca, R. Barrena-Puertas, R. García de Viedma, J. M. Luque-Pinilla, G. Sotres-Fernandez, J. M. Fernández-Sousa, X. E. Luepke-Estefan, J. A. López-Martín, J. M. Jimeno
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Abstract Background There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies. Case presentation Here
Externí odkaz:
https://doaj.org/article/655c07c636c64c15b2c0ae81c866ce47
Autor:
P, Aviles, R, Altares, L, van Andel, R, Lubomirov, S, Fudio, H, Rosing, F M, Márquez Del Pino, M M, Tibben, G, Benedit, L, Nan-Offeringa, X E Luepke, Estefan, A, Francesch, A, Zeaiter, C, Cuevas, J H M, Schellens, J H, Beijnen
Publikováno v:
Drug Metabolism and Disposition. 50:327-340
Lurbinectedin is a novel and potent selective inhibitor of active transcription of protein-coding genes, triggering apoptosis of cancerous cells. It has been approved for the treatment of patients with metastatic small-cell lung cancer with disease p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98ec718d13167a8c56d00b5f1d9a031b
https://doi.org/10.1124/dmd.121.000668
https://doi.org/10.1124/dmd.121.000668